trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Long-acting insulin analogues reduce the risk of nocturnal hypoglycemia episodes compared to NPH insulin in patients with type 1 diabetes.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
2 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Long-acting insulin analogues reduce the risk of nocturnal hypoglycemia episodes compared to NPH insulin in patients with type 1 diabetes?

Yes. Long-acting insulin analogues reduce the risk of nocturnal hypoglycemia episodes compared to NPH insulin in patients with type 1 diabetes.

Verdict: SUPPORTED · 2 sources for, 0 against · Last checked

The analysis

The retrieved literature contains reviews and clinical studies demonstrating that basal insulin analogues exhibit more favorable pharmacokinetic and pharmacodynamic profiles with a reduced peak profile, which translates into a significantly lower risk of nocturnal hypoglycemia compared to NPH insulin in patients with type 1 diabetes.

Evidence for · 2
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review.
2020
A narrative review on insulin therapy in adults with type 1 diabetes notes that basal insulin analogues offer a lower risk of hypoglycemic episodes, especially nocturnal, compared to older basal insulins like neutral protamine Hagedorn (NPH).
Get citation
A, J., C, G., A, M., N, L., T, T., L, C., AG, T., M, P., E, M., & L, S. (2020). Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review.. doi.org. https://doi.org/10.1007/s13300-019-00743-7

See more details
More for · 1
Real-world comparative effectiveness of analogue and human insulin on glycemic control in children and adolescents with Type 1 diabetes in Lebanon using continuous glucose monitoring data.
2026
A real-world comparative study in children and adolescents with type 1 diabetes found that analogue insulins were associated with a reduction in both overall and nocturnal hypoglycemia compared to human insulin.
Get citation
S, M., M, A., I, C., P, B., T, H., S, B., D, P., & P, P. (2026). Real-world comparative effectiveness of analogue and human insulin on glycemic control in children and adolescents with Type 1 diabetes in Lebanon using continuous glucose monitoring data.. doi.org. https://doi.org/10.57264/cer-2026-0036

What does the evidence say?

The retrieved literature contains reviews and clinical studies demonstrating that basal insulin analogues exhibit more favorable pharmacokinetic and pharmacodynamic profiles with a reduced peak profile, which translates into a significantly lower risk of nocturnal hypoglycemia compared to NPH insulin in patients with type 1 diabetes.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work